William Jl Rieflin
CIK 1182471 · Executive Chairman · last filed 2026-10-26
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
RAPT price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
333 OYSTER POINT BLVD.
SOUTH SAN FRANCISCO, CA 94080
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| LYCA | Director | — | — | — | $0 | 1 | 2026-10-26 |
| LYEL | Director | — | $13.62 | — | $0 | 6 | 2026-06-12 |
| RAPT Therapeutics, Inc. (RAPT) Delisted | Director | 11,840 | $58.01 | $686.8K | $258.2K | 11 | 2024-05-23 |
| NGM BIOPHARMACEUTICALS INC (NGM) Delisted | Executive Chairman | 0 | $1.54 | $0 | $0 | 6 | 2024-04-08 |
| XENOPORT INC (XNPT) Delisted | Director | 0 | — | — | $17.0K | 24 | 2016-07-06 |
| Anacor Pharmaceuticals, Inc. (ANAC) Delisted | Director | 0 | $10.19 | $0 | $0 | 7 | 2016-06-24 |
Holdings By Holder
| Symbol | Holder | Shares | Share of Total | Reported |
|---|---|---|---|---|
| RAPT | Direct | 2,250 | 19.0% | 2020-11-20 |
| By Rieflin Family Trust u/a dtd 4/3/00, William J. Rieflin and Prudence H. Rieflin, Trustees | 9,590 | 81.0% | 2020-11-20 | |
| Total | 11,840 | |||
| NGM | Direct | 0 | — | 2024-04-08 |
| Rieflin Family Trust U/A 4/3/00 See footnote |
0 | — | 2024-04-08 | |
| Total | 0 | |||
| XNPT | Direct | 0 | — | 2016-07-06 |
| Through Fund | 0 | — | 2016-07-06 | |
| Rieflin Family Trust U/A dtd 04/03/00 By Trust |
0 | — | 2016-07-06 | |
| Total | 0 | |||
| No longer reported | ||||
| By GRAT | 75,013 | — | last 2010-03-16 | |
| ANAC | Direct | 0 | — | 2016-06-24 |
| By Trust | 0 | — | 2016-06-24 | |
| Total | 0 | |||
Recent Filings · Page 4 of 6
55 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2014-12-12 | XENOPORT INC (XNPT) Delisted | Sell (S) | −11,010 | -$93.5K | EDGAR |
| 2013-06-07 | Anacor Pharmaceuticals, Inc. (ANAC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2013-05-16 | XENOPORT INC (XNPT) Delisted | Mixed | +5,000 | $0 | EDGAR |
| 2012-06-01 | Anacor Pharmaceuticals, Inc. (ANAC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2012-05-17 | XENOPORT INC (XNPT) Delisted | Grant (A) | — | $0 | EDGAR |
| 2011-12-16 | XENOPORT INC (XNPT) Delisted | Buy (P) | +10,000 | $38.6K | EDGAR |
| 2011-11-22 | XENOPORT INC (XNPT) Delisted | Buy (P) | +10,000 | $44.4K | EDGAR |
| 2011-11-09 | XENOPORT INC (XNPT) Delisted | Buy (P) | +5,000 | $27.5K | EDGAR |
| 2011-05-26 | Anacor Pharmaceuticals, Inc. (ANAC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2011-05-12 | XENOPORT INC (XNPT) Delisted | Grant (A) | — | $0 | EDGAR |
10b5-1: the filer ticked the box for trades made under a Rule 10b5-1 trading plan, which sets the sales (or buys) in advance, so they say less about the insider's view at the time than a discretionary trade. The plan's adoption date is shown when the filing's footnotes give it.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment, and an amended or cancelled notice is not listed. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes. Someone who is no longer an officer or director (or never was) files no Form 4, so for them a sale shows up only on a later notice, which lists the seller's sales from the 3 months before it. "No sale on file" means neither record shows one; a dash in Net $ means the value filed on the notice doesn't fit the stock's price (likely a typo).